Valvular Disease Flashcards
What are the indications for PMBC?
- Progressive MS (MVA > 1.5 cm2, T1/2 < 150 ms)
-
PMBC at CVC (Class IIb)
- Exertional symptoms →
- Stress test with hemodynamically significant MS →
- Pliable valve, no clot, < 2+ MR →
-
PMBC at CVC (Class IIb)
- Severe MS (MVA « 1.5 cm2, T1/2 « 150 ms)
-
PMBC at CVC (Class I)
- Symptomatic +
- Pliable valve, no clot, < 2+ MR
-
PMBC at CVC (Class IIb)
- Symptomatic +
- Pliable valve, no clot, < 2+ MR (does not meet) +
- Severe symptoms, NYHA III-IV
- NOT Surgical candidate
-
PMBC at CVC (Class IIa)
- Asymptomatic
- Pliable valve, no clot, > 2+ MR
- PASP > 50 mmHg
-
PMBC at CVC (Class IIb)
- Asymptomatic
- Pliable valve, no clot, > 2+ MR
- New onset A-fib
-
PMBC at CVC (Class I)
What are the indications for MVR in MS?
- Severe MS (MVA « 1.5 cm2 and T 1/2 ► 150 ms)
- Symptomatic –>
- No Favorable valve morphology, No LAA clot, < Mild MR
- Severe symptoms - NYHA Class III-IV symptoms
- Surgical candidate
***Class I recommendation
What are the contraindications to PMBV?
- Persistent LA or LAA thrombus
- Obstruction of IVC
- tumor, thrombus, therapeutic ligation, filter placement
- Bleeding diatheses
- Anatomic deformity resulting in rotation of the heart
- severe kyphoscoliosis
- previous pneumonectomy
- > Moderate MR
- Massive or bicommisural calcification
- Severe concomitant aortic valve disease
- Severe TS
- Severe functional TR with enlarged annulus
- Severe concomitant CAD requiring CABG
What is the recommended duration of Rheumatic Fever Prophylaxis?
- Rheumatic fever with carditis
- Residual heart disease (persistent valvular disease)
10 years
or
Until 40 years of age
- whichever is longer
- sometimes lifelong prophylaxis
What is the recommended duration of Rheumatic Fever Prophylaxis?
- Rheumatic fever with carditis
- No residual heart disease
10 years
or
until 21 years of age
- whichever is longer
What is the recommended duration of Rheumatic Fever Prophylaxis?
- Rheumatic fever without carditis
5 years
or
until 21 years of age
- whichever is longer
What are the medical treatment options for rheumatic fever prophylaxis?
- Benzathine PCN G
- PCN VK
- Sulfadizine
- Macrolide or Azalide
- only if allergic to PCN and Sulfadiazine
What is the medical therapy for chronic, primary MR?
no pharmacologic agent has been shown to slow progression toward surgical intervention
- ACE/ARBs –> decreased Regurgitant volume but no difference in clinical event rates
Why is MV repair recommended over MVR in primary MR?
- preservation of LV function
- lower operative mortality rate
- lower rate of long term complications associated with prosthetic valves
What subgroups of patients with primary MR have been found to have higher event rates or clinical deterioration?
- EROA ► 0.40 cm2 or
- Flail leaflets
What is the recommended medical therapy?
- chronic, primary MR
- LVEF < 60%
- surgery is not planned
- ACE/ARBs
- Vasodilator agents
****Class IIa recommendation
*****not indicated for normotensive, asymptomatic, LVEF ► 60%
Describe the management of chronic, severe MR
- Primary, Severe MR
- Asymptomatic
Describe the management of chronic, severe MR
- Primary, Severe MR
- Symptomatic
Describe the management of chronic, severe MR
- Primary, Severe MR
- Asymptomatic
What factors are required to proceed with TEER in primary severe MR?
- High or prohibitive surgical risk
- Anatomy favorable for transcatheter approach
- Life expectancy > 1 year
Describe the management of severe secondary MR
Describe the management of chronic, severe MR prior to proceeding with any surgical/procedural intervention
- Treat comorbidities:
- CAD Rx
- HF Rx
- AFib Rx
- Consider CRT
What is the treatment for acute, severe MR?
- Afterload reduction (may improve hemodynamic status by)
- reducing RV
- increasing LV forward SV
- increasing CO
- Sodium nitrorpusside
- Hypotension –> IABP
- Emergent Surgery = definitive therapy
What is the preferred treatment for chronic, secondary MR prior to surgical intervention?
- Medical therapy
- ACE, BB, Aldosterone antagonists –> treat LV systolic dyfunction and/or CAD
- reduces preload, afterload and reduces adverse LV remodeling –> secondary MR
- CRT
- to improve severe LV dysfunction with mechanical dyssynchrony
- may reduce MR severity
When is transcatheter (edge-to-edge) MV repair considered in chronic, severe, secondary MR?
- LV dysfunction (LVEF < 50%)
- NYHA class III-IV symptoms
- despite optimal therapy for CHF
- including Bi-V pacing
- Anatomy (favorable)
- LVEF 20-50%
- LVESD < 70 mm
- PASP < 70 mm
****Class IIa
EKG definition:
- Pacemaker malfunction, not constantly capturing (atrium or ventricle) “failure to capture”
- Pacemaker stimulus without appropriate depolarization
- at a time when the myocardium refractory
- May be caused by:
- lead fracture
- increased pacing threshold secondary to myocardial scar
- medications (flecainide, amiodarone)
- perforation
- electrolyte abnormalities
- displacement
What are causes of “failure to capture” in pacemaker malfunction?
- lead fracture
- increased pacing threshold secondary to myocardial scar
- medications (flecainide, amiodarone)
- perforation
- electrolyte abnormalities
- displacement
What are the age cutoff’s for mechanical over bioprosthetic valve replacement?
- Aortic
- < 50 years –> mechanical
- 50-65 years –> either
- > 65 years –> bioprosthetic
- Mitral
- < 65 years –> mechanical
- > 65 years –> bioprosthetic
What are risk factors for poor outcomes in severe AR?
- Symptoms
- Increased LVEDD
- > 65 mm
- Increased LVESD
- > 50 mm
- Reduced exercise EF
- < 50%
What test should be ordered in a patient with incidental finding of dilated aortic root (4.2 cm)?
Why?
- TTE
- Bicuspid aortic valve
Describe the risk categories in selection of TAVR vs. SAVR
What mechanical prosthetic valves require bridging anticoagulation?
- Bileaflet aortic valve with increased thromboembolic risk factors
- Caged ball or tilting disc prosthesis
- Mitral valve prosthesis
- Recent CVA/TIA
What mechanical prosthetic valves do not require bridging anticoagulation?
Bileaflet AV without other risk factors of thromboembolism
What are risk factors for thromboembolism in the setting a mechanical valve?
- Hypercoaguable condition
- A-Fib
- LV dysfunction
- Thromboembolism (previous)
When is a target INR 3.0 (2.5-3.5) recommended in regards to mechanical prosthesis?
- Mechanical AVR + risk factors for TE
- Older generation mechanical AVR
- ball in cage
- Mechanical MVR
What are the INR recommendations for On-X valve in the aortic position?
VKA + ASA
- First 3 months –> INR 2.5
- > 3 months –> INR 2.0
What are the recommended anticoagulation strategies in pregnancy and prosthetic valves?
- Continued VKA
- 1st Trimester UFH or LMWH –> VKA (sequential therapy)
- UFH/LMWH (entire pregnancy)
*******UFH prior to delivery
What is the first step in assessment of prosthetic valve (AV or MV) with high gradients after surgery?
Calculate Indexed EOA
- Indicate Patient-Prosthesis mismatch:
- Aortic = EOA < 0.85 cm2 / m<strong>2</strong> (severe = < 0.65 )
- Mitral = EOA < 1.2 cm2 / m2 (severe = < 0.9 )
What is the second step in assessment of prosthetic valve (AV or MV) with high gradients after surgery?
TTE, TEE, Cinefluor –> to identify
- Gradient increased during follow-up
- Aortic > 10 mmHg
- Mitral > 5 mmHg
- abnormal leaflet morphology / mobility
- DVI:
- Aortic < 0.30
- Mitral > 2.2
- Difference between measured EOA and reference EOA > 0.30 - 0.4 cm2
- EOA and DVI decreased during follow up
YES –> consider prosthesis stenosis
NO –> consider
- High flow state
- Technical error
- Localized high gradient (bileaflet valve)
Describe the risk/benefits in anticoagulation strategies used in pregnancy with prosthetic valves?
- VKA
- Lowest likelihood of maternal complications
- Highest likelihood of fetal complications (1st trimester (particularly) + dose > 5 mg) –>
- miscarriage
- fetal death
- congenital abnormalities
- Reduced dose < 5mg/day –> decreased (not eliminated) fetal complications
- Reduced thromboembolic complications (compared to UFH/LMWH)
- UFH/LMWH
- increased maternal complications
- greatest number of successful live births
What are the anticoagulation recommendations following bioprosthetic valve placement?
- ASA daily
- indefinitely if no contraindication
- SAVR
- VKA –> 3-6 months (Class IIb)
- TAVR
- VKA –> 3 months (Class IIb) or
- DAPT –> 3-6 months (Class IIb)
What is the recommended anticoagulation strategy in patients receiving TAVR who are unable to be anticoagulated?
DAPT x 6 months
- dc Clopidogrel after 6 months and continue ASA indefinitely
What is the recommendation regarding ASA in patients with valve replacement?
ASA daily (indefinitely) + VKA
- decreases incidence of:
- major embolism or death (1.9% vs. 8.5% per year; p < 0.001)
- stroke rate (1.3% vs. 4.2% per year)
- overall mortality (2.8% vs. 7.4% per year)
- Increased bleeding (not statistically significant)
What findings on exercise stress testing, in a patient with asymptomatic, severe AS, would merit intervention?
Symptoms
or
Inability to augment BP by 20mmHg
or
Decrease in BP at peak exercise
What murmur is related to the Gallavardian phenomenon?
Describe the murmur
- AS (degenerative or age-related)
- harsh murmur at the base + musical murmur at the apex
- due to the high-frequency components of the AS murmur radiating to the LV apex
- often confused with MR
How can these murmurs be differentiated?
- AS (age-related or degenerative)
- MR
- AS (age-related or degenerative)
- Systolic ejection murmur
- harsh at base
- musical at apex
- increases with bradycardia or after a pause (PVC)
- Systolic ejection murmur
- MR
- holosystolic
- not affected by HR, PVC
Describe the valvular lesion associated with these hemodynamic findings
- Large LV to aorta pressure gradient
AS
Calculate posthetic valve EOA
CSA LVOT x VTI LVOT
VTI jet
Describe the valvular lesion associated with these hemodynamic findings
- large V wave on PCWP
MR
Describe the valvular lesion associated with these hemodynamic findings
- large V wave on the RA
TR
Describe the valvular lesion associated with these hemodynamic findings
- increased PA O2 saturation
Left-to-right shunt / VSD
Describe the valvular lesion associated with these hemodynamic findings
- large RVOT to PA pressure gradient
PS
Describe the effects on cardiac auscultation and murmur as AS worsens
- diminished ejection sound/intensity of A2
- murmur peaks later in systole
*****PVC –> murmur increases
What can cause the murmur of AS to intensify or worsen?
PVC
Describe key differences between the murmurs:
- Acute AR
- Chronic AR
- Acute AR
- diastolic murmur may be short
- mitral valve might close prematurely (S1 softens) and
- mid-diastolic rumble of relative mitral stenosis (Austin-Flint murmur) may occur
- Chronic AR
- holodiastolic murmur
Describe the effects of cardiac auscultation/murmur with worsening MS
- A2-opening snap interval in MS shortens –>
- as LA pressure rises and
- approaches that of the aortic early diastolic pressure
What is one finding of bicuspid aortic valve fusion that carries prognostic implications?
Right-Noncoronary cusp fusion –> higher incidence of aortic dilation
What is the monitoring recommendation for BAV?
Annually (if)
- significant aortic dilatation > 4.5 cm
- rapid rate of change in aortic diameter > 0.5 cm/year
- FH of aortic dissection
What is the cutoff for aortic imaging with Echo?
visualization of the aorta up to 4 cm distal to the valve
What are the indications for surgical intervention in regards to aortic abnormalities in BAV?
-
Class I
- aortic diameter > 5.5 cm
-
Class IIa
- aortic diameter 5.1 - 5.5 cm + rapid growth ( > 0.5 cm/year) or FH aortic dissection
- aortic diameter 4.5 cm + valve surgery (severe AS or AR)
What is recommendation regarding Warfarin use throughout pregnancy?
Continued throughout pregnancy if dose « 5 mg/day
- embryopathy from warfarin appears to be dose dependent
- switch to UFH just prior to delivery
- Class IIa recommendation
What equation can be used to obtain MVA during cardiac catheterization?
- Hakki equation
- MVA = CO (L/min) / √mean pressure gradient (mm Hg)
What are common errors / problems when obtaining MVA during cardiac catheterizaton (Hakki equation)?
- subject to errors in estimation of CO
- failure to simultaneously measure left atrial (LA) and LV pressure
- Concomitant regurgitation
What is the problem when utilizing PCWP in place of LA pressure to determine MVA during cardiac catheterization (Hakki equation)?
measurement of PCWP in place of LA pressure may
- overestimate gradient and
- underestimate MVA
Define patient prosthesis mismatch (PPM)
effective orifice area (EOA) of a prosthesis is too small
relative to the patients body size –>
resulting in abnormally high postoperative gradients
What are two situations in which bioprosthetic valves are utilized over mechanical valves?
- Pregnancy (anticipating)
- History of IVDA
What are 3 priniciples that must be understood by both sonographer and interpreting echocardiographer in the assessment of prosthetic vavles?
- All prosthetic valves have some inherent obstruction (which varies based on valve type and size), which can make differentiating between normal and pathologic gradients challenging.
- Prosthetic valves have inherent transprosthetic regurgitation that must not be confused with pathologic regurgitation.
- Acoustic shadowing and other artifacts such as reverberations can make evaluation of the structure of the valve and presence/degree of regurgitation difficult